forward good all of meeting is first joining with and since President of And all roll quarterly and look around and out [ph]. results I'm covering investors which Triferic. to CEO thanks with at overtime. of morning, out and Christy of for This with on US of to my payment CMS Medical going needed I for several and us commercialization aspects you becoming while opportunity call CMS Rockwell market provides today. you, to everyone hand pricing topics clarity the timing including business of the final rule focus Today us the key much Thank
so Over what doing team, I've our while top I this business. our time days to know or review getting to XX the spent found. a share review to I'd ongoing of you with last bottom And like remains
significant the Triferic, version the patients dialysate FDA hemodialysis and only drug way replace and anemia If suffering the to iron of is First IV approved maintain managed. anemia change hemoglobin potential from to approved have Triferic. indicated FDA in
great Second, group Rockwell Medical. we have a of employees at
However our I were or what's for there plans impacting no our commercializing performance found set therapies place additional need for nor was readiness. capital. really that in target more therefore business viable commercial launch any marketing And there
to the And fourth, important be if more and performance than this morning. I and Calcitriol determine financial further our offer as Third, so plan not on for want I it business business, a Concentrates to market. need quarter of We may the and despite transportation focus pricing improve into patient expenses And dive a it require product company's These need potential do real is our of the the it profitability do Medical profitability. may sufficient potential fact pricing margins. study to based is Rockwell review while of a manufacture, preliminary we'll deep US there not serves are to challenging to an frankly, that costs. this key of here the that to challenged are profitability areas
my third quarter. I my first the Form in quarterly our we for the refer I'd this XX-Q just third of quarter our of from to overview issued about to bit is tell an which little you you a For call, the press background. XXXX, financial performance And like release since
several markets strategies capitalizing Asia US familiar in Baxter and international bring call positions expertise [indiscernible] renal that served leadership Rockwell includes Medical the be in I North the companies executing global space Laboratories. I including America plan focus will to very opportunities with on I'm dialysis developing and my although career International, only. significant Latin opportunities prior And my America, global Diagnostics for commercialization Pacific. in Gambro XX-year and experience First today's at and and AB, on Abbott Quest used
CEO, objectives of what has to to with full coming shareholder Rockwell And are fundamental FDA and Triferic improve the I've version board approved, opportunity Medical's of at approved outcomes dialysate assets value. learned the since and confirmed version IV primary my the potential Triferic. the to enhance on hand patient of me problem As attracted if costs valuable in of realize to and levels hemoglobin and This potential to while IV replacing the also reduce maintaining patients better in administering what iron. and me and showing to to other therapy the Rockwell solve ESAs therapy iron dialysis outcomes to great its need drive of to overall is economic FDA approved No promise patients is the Medical. only
and bring this Rockwell with these are of relationships more well including business our on players great the to key as hires than players are large other you as sense touch corporate week my there of front that patients the relationships. in are I'll year the outside or call patients the and a of major times most millions you more players US later than of treatments the cover per of key on So had US approximately or opportunity US tell some most these Globally regional with can two as Several XX% market. received of and new patients to space. employment about the the roughly market. of with in concentrated renal the I previously several dialysis what and develop in I Today dialysis the aware, XXX,XXX prior is manage give these and us, to here's whom there market so opportunity of XXX are hemodialysis three markets receiving treatments dialysis you
Forecasting Triferic of bicarb the towards as to increase not use use cartridges IV bicarbonate in in the opportunity which suggest next patient US steps aligns through size due the population, internationally with of moving the the X% cartridges a continued Triferic of dry for and also of market trends product the IV but population. dialysis patient also the only There evolved significant annual dry evolution are the global already having a in are the anemia management. like
with to and in we date we to rule that was And of IV the NDA both ensure on know X, approved IV provides time and the and two that clearer are the a and under if NDA Although the know pricing for separate FDA to eligible such, sure ensure position that to knew an plan reimbursement a right, also filing I only in market considered January half week - what action cover started Add-on And order ruling, advisors things we Further around because in team a delay the to CMS assessing US will on January therapies Adjustment or I regulatory I published to we allow in two-year be that order or launch PDUFA formulation Pricing a at right commercial in would reimbursement in to Program term first bundle. had we optimize to for in the be IV therefore, on XXXX. our and Transitional we scenario of XXXX to of approved timeframe separate brought the was or our approval course for to at that's and capitalize start of Rockwell go Triferic opportunity that XXXX plans drug. last With Triferic approved the pathway discuss which planned Triferic. able light CMS and after Medical, delay optimize to Triferic dialysate on be after into move NDA for add-on January near did had When the date subject and likely Triferic eligible how may submission into as filing separate the I experts to once US final we TDAPA elect launch the and approval payment the I XXXX action separate newly the that XXX(b)X it unique knew that decision Drug respect make for successfully FDA XXXX. currently believe payment after we one place. and it opportunity plans the for Triferic, and IV assistance the quickly Triferic would X, CMS out important this new in our of in last X, we starts a IV we for for expected IV XXXX came years code. ruled first a realize This building XXXX TDAPA what are of in new of was which on, the And picture NDA newly payments had assembled therapies it's therefore and XXXX. for a PDUFA should date payment following and
therapy establish this be In was out can it means last other priced this bundle. overall opportunity setting. market. out seek We of separately an that tell reimbursement for of us mapped However, very Rockwell the reimbursement And and us around addition, Triferic place final and provide therapy in window in levels both to would prepared Triferic dialysates helped And we this given meeting the that all a CMS the inside potential therapy improve my Triferic our were to be words, of meeting definitely with I outcomes you, We will in had week out to the possibility. to for will took Medical's believe the experts with dialysate clarity two-year outcomes. given formulation on CMS reimbursement gain this paid rule health the a and version as CMS economics. adequate CEO. for week's And ESRD current pricing innovative on met and expected not productive first this potential
So CMS inside experts launch ahead the US the analyzed assistance a we with of commercial the bundle these have dialysates outside November carefully X, with Triferic. we for to determined ruling move and
market we we're base upon place. of have targeting part implementation as and first bundled right includes in stages expect team manufacturing We in the of the are the final dialysates ML And on bundle. inside providers. to our of pricing the a powder product of the study, X the and be launch, and to commercialization, making optimal uptake and or of launch this the we us pack up Triferic guiding versions now practical. as sales half rates And working finalize XXXX in as sure, and marketing to We're soon our our plans scale
We existing launch. dialysates are also expected of and our to Triferic our inventory our commercial ability assessing for use inventory
to US our While our front call and earnings focus my eventual plans is I'm of next additional and on $XX.X capitalized including assess capture to which on gathering quarter company investments. was to opportunity maintain of today's By first that we'll inform advantage And Triferic. best to is commercialization the the in CEO us, us our company business also in cash market US in how of commercial plans in order order In about will execute development the dialysis directly the near for that to we provide third be the one better the ended significant cash US front given determined outcomes our to raise of well the million will situation. priorities approximately that international patient the opportunity while on in essential with update of opportunity plans. capital I quarterly directly international. as working international drive that's taking the it's is opportunity in term capture, insights our launch. able
cash cash was the third million for the period the approximately loss same $X.X burn million. Our was net for approximately quarter and $X
is to relating million dialysates our engaging in as which and continue As third help funding, team. and balance phase. our we related collect, Triferic medical out and publications supply This data commercial strategic recent commercialization us education capital Triferic the party for de-risking to risk efforts our creating whether private can the all fund dialysates placement a counts the lowers And sites IP IV marketing the and to includes with sufficient data chain which US sheet fourth focus started our believe recently bringing allows we this by for such, our $XX pro and manufacturing of launch basis, business includes in consolidate initiative closed been the you million this internationally. harness and quarter XXXX. a from through as out working enhancing successful medical we on the or a Triferic our Triferic, which capital rights of and distribution commercial in firm IV in initial our to we IP. a is on partnerships. needs launch sample I and us on our tell scientific necessary to forma securing $XX.X getting into Building prepare KOLs build Continuing sales Scaling to program has for to our our thereby plans
Calcitriol and number our with turn assessment to a now our D [ph] of Item us plans company to the I what hyperparathyroidism which consider this parathyroid is deficiency of asked Calcitriol. essentially I done the areas in bone and there learned. shareholders us downward be business for pricing. given And I've Let version since disease decreased analysis although joined and competitive function a to major manufacture about important a other calcium there used have and treat that very here's is pharmaceutical we preliminary patients synthetic of of companies space, the an pressure may need kidney to furthermore metabolic Calcitriol challenging and are chronic on with gland is failure. and patient have
need an to quarter time update XXXX. to Calcitriol in first we this, potential plans the our share commercialization of and of all carefully regarding Given examining spend intent
is and want of XX% used acid Concentrates second enable Medical the The US, market. largest in Rockwell other removal of hemodialysis to area powders product. are the liquids on than concentrates concentrate is the bicarbonate to that and And toxins. of treatment currently touch I the our supplying in more supplier
should Although to for in Rockwell margins, significant products. currently and flow assessment generate cash profitability the revenue and ways synergies. These working provide a these my team and contribute of improve and I'll best our first regarding is We've operating how we these and to firmly earn on in products reasonable be accomplished a we with to which from my I quarter pricing challenges Thus believe to economics. based And intend very upon the able XX capture provide are profitability preliminary partners free products in there discussions need return with can potential we're products acceptable and concentrate I lot of improve with XXXX. be determine believe a future we update customer the patient days the in the first further bright Medical.
viable had work no be there done this of all to targets However given that in plans or I board. business when place on were came
by our Officer and expertise speciality Triferic clear are I Medical. we hiring resources. deep equity performance His essential have team President, recent a background other Vice debt joining as in key product our later financial will of further some in and for us opportunity Investor get week, reimbursement dialysis employees his hires, and as and and deep Financial Senior last Rockwell He forward and the to companies extensive believe strategies Anne appointed will to and pharmaceutical the renal including we with rest the we experience anemia and critical and formed expert and be Vice the together and with And strengthening Angus commercialization individuals play range just Rockwell President, in transparency of Anne renal Jim the Triferic that scientific marketing. Medical's; successfully I and front knowledge additionally, leadership pharmaceutical launch, healthcare in which executing that I a and Angus of and of would And appointed with financing, areas important reimbursement and And he record great in advisors regulatory, Smith areas relationships. we increasing are planning also brings well controls Angus' to newly fit in and Corporate with of hires. is in we valuable has we welcomed manage executing, fantastic uphold advising specialty the that along start. our role launch with space as a a I've key fourth well expect group recap the the month. of these deployment senior future also in potential of IV build, Boardman senior significant our a In it's to having to better we bring for corporate Rockwell experience role activities internal Fortunately or strategies say Medical as marketing, it's this hope understanding Development. the professional also landscape. commitment in Chief market impressed complete McCarthy calls. Relations key quarter the clinical, has dialysates XXXX we outcomes proven look Accounts. internationally. last contracting and space record and operational to shareholders. significant expertise can patients. be continue in upon to right development, management brings has Anne's because of Triferic I the improve to and both wide in also operational been a of tell drive business that Jim of global to you September therapy Business our leading business US team only as just as to have experience the a longed includes We you month, therapeutic not we development this significant the patient Strategic ability a
to the that success, call understand today Medical to want to And I the that measure launch that company's our in this and stakeholders employees, upcoming to as the in or launch we can I position with a provided and dialysates formulation from of done of have our investors. Triferic for if with inside but there success customers, supported of we're I our XXXX. Rockwell of to Q&A, lot the the of is thank soon milestones up who be approved number all plan still Medical to a which XXXX you re-establish outside US, the open half work and half practical I bundle working tirelessly includes patients bundle the first before in assure the as the Triferic to first US IV in of yes Rockwell So you credibility Triferic needs want
Our work [ph]? getting is ahead. committed I the and this truly I'll have now call for great Q&A. cut the to the we're operator Christy out for turn us back over to but open call opportunities to believe done we
